Dermata Therapeutics (NASDAQ:DRMA) Announces Earnings Results, Hits Expectations

Dermata Therapeutics (NASDAQ:DRMA) posted its earnings results on Tuesday. The company reported ($0.55) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.55), FiscalAI reports. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.03 million.

Dermata Therapeutics Stock Performance

NASDAQ:DRMA traded down $0.04 during mid-day trading on Thursday, reaching $0.67. The stock had a trading volume of 5,943 shares, compared to its average volume of 1,625,276. The stock has a market capitalization of $3.33 million, a P/E ratio of -0.20 and a beta of 0.63. The firm has a 50 day moving average price of $0.99 and a two-hundred day moving average price of $1.27. Dermata Therapeutics has a one year low of $0.60 and a one year high of $4.66.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dermata Therapeutics in a research report on Monday, October 26th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has an average rating of “Sell”.

About Dermata Therapeutics

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.